BioMarin Pharmaceutical (BMRN) has been under a strong bear grip, hence the stock is down -3.02% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.29% in the past 1 week. The stock has risen by 4.6% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.22% in the past 4 weeks.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.22% and the fifty day Moving Average is 6.57%. BioMarin Pharmaceutical Inc. is up 8% in the last three month period. Year-to-Date the stock performance stands at -8.15%.
BioMarin Pharmaceutical (BMRN) : The consensus price target for BioMarin Pharmaceutical (BMRN) is $118.64 for the short term with a standard deviation of $12.04. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $150, however, the pessimist price target for the company is $99.
BioMarin Pharmaceutical (NASDAQ:BMRN): stock turned positive on Friday. Though the stock opened at $95.09, the bulls momentum made the stock top out at $96.36 level for the day. The stock recorded a low of $94.415 and closed the trading day at $96.22, in the green by 1.32%. The total traded volume for the day was 1,294,891. The stock had closed at $94.97 in the previous days trading.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).